semaglutide and kidney issues cuts risk in obesity | Journal of Endocrinological Investigation ADA 2026 - High-dose subcutaneous

The facial consequences are increasingly well-known, with many experiencing what is termed 'Semaglutide Face' or 'Ozempic Face'

What to Expect During Your First 90 Days on GLP-1 Therapy Dose titration is the single most important factor determining whether patients tolerate GLP-1 medications long-term

In the ATTAIN-MAINTAIN trial, participants who had previously completed 72 weeks of treatment with Mounjaro or Wegovy were re-randomised to receive either Foundayo or placebo

Ongoing monitoring and tailored interventions are critical, especially as patients may experience fluctuating weight or continued treatment with GLP-1 RAs